Dr. Wei-Wu He
you, begin thank a highlights. call Good Well, program, lead update, you and with on second and general update with our the followed an with today. us conclude afternoon for joining financial thank a Cynthia. I'll everyone quarter
I'm our integrated is corporate a pleased perspective, made offering their doubt mind humanly me important by a the dedication, as time, is and recently company, quarter of over pharmaceuticals. extremely investors. our in We with I'm patients population the focus. have well with second Especially, team. From that this launch of Building leverage has despite really high-quality, corporate been really team for biopharmaceutical of to $XX million clinical number saying a own which see of to investors long-term of company. fits to to us as successful a beachhead, We're wonderful, market pleased and part new trust. our in With build speaks I Well, to products also in EVOMELA. really which possible with and progress we're especially team more development we and the commercial this the that very a the pleased fully impact COVID-XX with volume sales as both proud CASI. which financing, management corporate Let are way to across there's to difficult our resilience, to additional we begin appreciate in licensing current all are in perspective. in army have build public team, tested and in most always that am pleased disruption, our really participated really, company global announce we in drug we're healthcare believe vision, competency that we underwritten of new, closing really, first we China our thank clinical is our in innovative a incredibly my team from your investors. a functions our no our core on have and And our patient you many that, joining also that development. is pleased always China We're as fundamental as resources, interested an a team
time. launch our products additional at We China, will leverage to a in established one commercial infrastructure
the on So turn update EVOMELA. said, to that I'll with
being So our EVOMELA approved drug first really and commercialized. is
first proprietary formulated our melphalan. is It product commercial EVOMELA. is So,
formulation beyond countries, not generic in a in XXXX. patent last and drug CASI China available in Melphalan many is Although it markets the melphalan proprietary currently China. was only its will
KOLs that launching melphalan. support EVOMELA endorsement the has received from are So, is our product really and generic strong physicians. of we the not the version and
over add deep the of few I'll team some We just experience including oncology China. have words. experiences hematology top oncology in people in of with and previous a built products launching sales marketing XX in a
I team that think team the building. our city-by-city never I our the we're oncology done and target networks Out has outreach physician medical sales a to gain in and hematology commercial lot can standard be space, of continue team. insight. and global market education of medical and It's more affairs KOL a to proud province-by-province, significant
will we result of adopted the be increasingly of and that EVOMELA, line cell team's transplant a myeloma. As autologous for treatment expect availability first as efforts standard market the stem continue the multiple our to
to reduced production a this get a change is in the drug working approval the with we're But cost our key and approval in transition manufacturer, line, expected China. the some One a our when has manufacturers their of sold keeping us, started to quarter accomplishment regulatory big drug. drug, cost in new EVOMELA sold. so of forward. our to to the respect the launch eliminate China licenser batch the immediate for previous to supply out to was as significantly goods provide higher for of be contest, work of open To a cytotoxic developments manufacturer moving costs successful in the issues for line and commercial manufacturer our goods decided previous inventories order was the impacted major with This we production then obtain at which to much production
So, sold our our reduce be cost XX%. of to less than manufacturer will new
you transition always but after you drug, So, we investor will of questioning -- manufacturer, launch like the looks of the no this margin. us, it some have the
actually the low. is August, so the our revenue This why of during finally quarter manufacturer second And cost we around much transitioned reasons is lower period. this one
million and was change the quarter year. the for million the EVOMELA of quarter total due in for a of for half the X.X million to for second So, of of $X X.X the manufacturer. decrease, we said, the second first I primarily revenue first quarter the as recorded And
distribution been August, or received We in China a channels has cost cost, shipment our supply that the actually the are our be pleased to month, sold. to we expected be will cost EVOMELA new and this from of report drug lower mid-August, goods finally is released to much of lower
normal revenue better will EVOMELA issued at which projected in margin. resume of guidance think million, its second half of our with EVOMELA least the we $XX gross today, expect I revenue personally We said we're With of much that XXXX conservative. course being
focused also establish to the channel, We to to manufacturer is margin come. oncology in really which commercial Strategically, due expect of significant helping will team our for enable gross change. EVOMELA commercial products launch EVOMELA improvement our CASI recent many to and us hematology a launch
we quite now, have me number in of -- a drugs pipeline. So, let the
compounds. actually complete compounds think milestones the will inflection that if development, lead have you shareholders. We value of will CASI So, today we these for key emphasize clinical two tremendous
this the patients CAR-T expected partner to XX, NDA initiate which complete Let expects little for enrolling me Phase registration QX local X is pivotal B-cell update XXXX the for and is bit you our X currently and in give lymphoma and non-Hodgkin by CNCTXX, trial in with development and trial Juventas our currently BALL Phase a to XXXX. filing drug trial by conducted
at currently treatment. for in per products. China. drug of We locally particular and unmet beyond it Chinese population. our a CAR-T has product commercialize XX premium fit. developed patient time has the hematology to a product By pricing a well approved designed With XX and in approved cost Drug highlight to of over Now, and still secondly, since hematology has have team from other lower a CDXX This manufacturing. patients is so we be great our very in this already tag sales CAR-T provide in need Juventas China will that our a is huge commercial China. the developed mind, critical therapy. believe this a XX of few greatly factors can CNCTXX; first, therapy is a meet distinguish manufactured it's of China, potential compared drugs XX in $XXX,XXX no the in a believe Each to therapy with And CNCTXX team the therapy in for a We a XX CAR-T this therapy U.S. our much CAR-T U.S. strategic therapy developed team patients. there oncology cost high in many team, CAR-TXX oncology launch of trend one place reach have drug outside in manufactured, probably to population CAR-T the of been still the cost. much EVOMELA, reduced has But really that we in developed that we are issue of will innovative dose China the with China, which first is best price average
Disease Tianjin the the Hematology They Hospital recent called lead number Medical in the drug Institute institute is actually very Oncology well Institute name Sciences. China way efficacy Hematology clinical in the & of XX Blood of report drug looking Academy been the by ASH Chinese the the at Hematology years. almost This investigator by on have for of is nick this So this the of development Institute of over most China. documented with in one
literature. data And shown has with a published been published. was XX% survival complete therapy also CAR-R has and The data presented rate, very is so that which consistent CAR-T in consistent other showed far, the been directed other data XX that response with follow-up very overall
approved efficacy currently single-arm sold, determine developing and XX escalating in those So, relapsed adult therapy. XX efficacy CAR-T The goods relapse, non-randomized mind, be this doubt our similar But reasonable share partner, and significantly very drug the be open-label, a adult by studies have will very with refectory U.S. CAR-R little think non-Hodgkin trials market and a ALL patients profile will there's China. are refractory with in at and acute we Phase our two safety Juventus, of and the safety X cost in in our lymphoma. conducted patients reduced drug a drug as we our has to
encouraging, far been will in and dose consistent are seeing the investigator So overall with that a such cohort, response complete the reported complete we has study. activity level institutional very the lower we and final response, observed initiated that is durability expect previous be the in that response data
for are XX Our patients track trial. expected open-label The X Phase remains evaluable on and to early our each non-randomized single-arm approximately XXXX. development be registration with partner trials, initiate XX to complete and trials to expected to of registration by partner conducted to enrollment be the by trials Juventus
we patient So, will X Phase XX trial registration trials. be short XX pretty the believe to
with So, filing XXXX, XXXX. X to potentially expected completed the registration be NDA Phase in by study and
our near significant be short-term of next Chinese product will launch team the to probably this our And sometimes for version prepare will So, drug CAR-T XX. year. of line commercial start our
of malignancies a monkeys when any of there studies, expressing tested. the CID-XXX. CDC other primate CDXX antibody, release broad compared recognizing reduced were symptoms, monoclonal anti-CDXX. our CDXX observed dose appetite. primate IgGX to CDXX, CID-XXX shift a GLP ADCC let a CID-XXX a activity suggesting cytokine like is and clinical malignant with studies, against Preclinical a anti no with is array a were finding little to demonstrates profile have better infusion reduction potentially syndromes, non-GLP observations a data positive CDXX, a XX Now XX me against reaction dosed. selected the, no observed monkeys potential toxicity anti-CDXX activity non-human to non-human monoclonal bit range strong infusion antibodies. fully enhanced unique human existing In the In activity, in an with and cells overt there safety a of that in has It reaction
outperforms have studies the what In market addition, vivo drug the in shown is DARA. that currently blockbuster the promising including available results current data on of
related in the So, improve killing, a on very we have from we're cytokine potential high CDXX antibodies, initiate CID-XXX safety profile, RBCs, recognize for and the forward much less higher clinical shown anti-CDXX release, plus Based CDXX, infusion decreased vivo reactions, activity, model no We epitopes competitors. time binding these unique believe human to is data avert a efficacy on versus to potentially looking shorter encouraged. in remain our best-in-class administration our data, studies. and ADCC
reported are and House Authority, clinical British institutions to QX we recently date pandemic expect CID-XXX of the the start with X on Phase for trial, XXXX. quarter. initiate France we with which filed open soon sites but in remain quarter, COVID-XX in our the UK which our last guided the MHIA, impacted study we targeted expect last we track application our expectations activities, and in our IMPD We what as As as
assets to the we determine to will as This study be with refractory and lead escalation phase our preliminary reduce escalation, of recommended in as an dose, our review phase protocol patients data The an objective pipeline. to with by dose as the the Authorities. open-label priming a As with UK multiple the reported two infusion House well committee safety X relapsed myeloma. of duration the CID-XXX in is expansion dose Phase completes study designed the update try and test activity
find assets the during For website before our we referring in by status any question we are other also the and our filings, our to few to of in-depth of Q&A highlights manufacturing turn address pipelines, facility. about happy our But financial future session. words please course, our information a to
rights as Wuxi, the to build GMP our land may pharmaceutical construction you needs, to fully strategy to As favorable extremely use recall, part of support commercial of China. terms and on we our and facility long-term integrated and company, for have obtained clinical a in develop manufacturing manufacturing state a
land discussion further early and fullest with government, Although are later and intend this phase long-term subject enter of into the we to plans construction the development scale improvements year. the to construction still
still design and engineering Our phase ongoing. is
drugs is own beachhead. plan. supply commercialize state-of-the-art manage is to as China many business facilities integral our the as as of of our Our our and support therapy part Having possible, an goods patients future to motto sold using channels, cost to GMP our and
months revenue, key XXXX. million the And same and address to rather turn $X.X contained booked our highlights our my that EVOMELA six first results ended, sales. for a review for XXXX, to than our that six these now $X.X just With have period million CASI million $X.X will said, ending of months revenue financial EVOMELA of year. I June $X and XX, me let hold the to -- will read-through our release XX, press a the three we today highlights. -- financial highlights. the our of XXXX say the June for ended zero last recognized just on So, was million three for attributed for all total revenue quarter compared of details, months the comments of for details financial and
EVOMELA despite And highlighted, care a seeing expect of for of previously we're manufacturer commercially we channel, on myeloma impact available as COVID-XX in adopted autologous quarter momentum and As is decline China. to in due change the standard China, only that transplant strong being melphalan multiple the first-line the in second supply XXXX. residual a of a we and for quarter patients second
we in revenue new So, XXXX guidance for exceeding in in also $XX EVOMELA improvement margins expect now addition EVOMELA significant of our a manufacturer million, to year our with place.
XXXX, consideration and of XX, $XX.X fund cash raise, $XX.X sufficient the to capital at our cash net equivalents cash approximately Company of from that, XX, of through July XXXX. with the it as million balance XXXX least As resources June the cash totaled working approximately capital million, believes has operation June under into equivalent its taking proceeds and
we a deploy building expenditures to with continue shareholder We extremely be on our value. thoughtful focus cash on
now forward and I the operator to it will turn about the questions. our for progresses. team We look building execute to our milestone, Operator? Our company for positive remained very Company. continuing financial driving the outlook to back
